The aim of this trial is to conduct a randomized, multicenter, placebo-controlled, double-blind clinical trial to determine the safety and efficacy of Finerenone in reducing proteinuria and protecting renal function in patients with IgA nephropathy.
The primary endpoint event was the change in urinary albumin/creatinine ratio between the two groups at 12 months of treatment.